ZSAN Key Statistics, Chart & Performance
The current stock price of ZSAN is 0.5576 null. In the past month the price decreased by -67.77%. In the past year, price decreased by -98.31%.
ZSAN Latest News, Press Relases and Analysis
ZSAN Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 24.98 | 216.75B | ||
| ISRG | INTUITIVE SURGICAL INC | 66.11 | 201.78B | ||
| BSX | BOSTON SCIENTIFIC CORP | 33.01 | 144.35B | ||
| SYK | STRYKER CORP | 27.62 | 139.09B | ||
| IDXX | IDEXX LABORATORIES INC | 56.93 | 57.33B | ||
| BDX | BECTON DICKINSON AND CO | 13.36 | 55.21B | ||
| EW | EDWARDS LIFESCIENCES CORP | 33.19 | 49.49B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 17.82 | 37.26B | ||
| RMD | RESMED INC | 25.37 | 36.66B | ||
| DXCM | DEXCOM INC | 34.78 | 25.23B | ||
| PODD | INSULET CORP | 69.02 | 22.19B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 11.41 | 18.30B |
Related stock screener links
About ZSAN
Company Profile
Zosano Pharma Corp is a US-based company operating in Health Care Equipment & Supplies industry. The company is headquartered in Fremont, California and currently employs 40 full-time employees. The company went IPO on 2015-01-27. Zosano Pharma Corporation is a clinical-stage biopharmaceutical company. The firm is focused on providing rapid systemic administration of therapeutics and other bioactive molecules to patients using its transdermal microneedle system (the System). Its System is designed to facilitate rapid drug absorption into the bloodstream, and to provide an improved pharmacokinetic (PK) profile compared to original dosage forms. The System consists of a three cm square to six cm square array of titanium microneedles approximately 200-350 microns in length, coated with a hydrophilic formulation of drug, mounted on an adhesive patch. The company is focused on development of its lead product candidate, M207, a formulation of zolmitriptan, which is used as an acute treatment for migraine. Its zolmitriptan formulation is delivered utilizing its system. M207 is designed to provide rapid absorption of zolmitriptan into the bloodstream without dependence on the gastrointestinal (GI) tract.
Company Info
Zosano Pharma Corporation
34790 Ardentech Ct
Fremont CALIFORNIA 94555 US
CEO: Steven Lo
Employees: 40
Phone: 15107451200.0
Zosano Pharma Corporation / ZSAN FAQ
Can you describe the business of Zosano Pharma Corporation?
Zosano Pharma Corp is a US-based company operating in Health Care Equipment & Supplies industry. The company is headquartered in Fremont, California and currently employs 40 full-time employees. The company went IPO on 2015-01-27. Zosano Pharma Corporation is a clinical-stage biopharmaceutical company. The firm is focused on providing rapid systemic administration of therapeutics and other bioactive molecules to patients using its transdermal microneedle system (the System). Its System is designed to facilitate rapid drug absorption into the bloodstream, and to provide an improved pharmacokinetic (PK) profile compared to original dosage forms. The System consists of a three cm square to six cm square array of titanium microneedles approximately 200-350 microns in length, coated with a hydrophilic formulation of drug, mounted on an adhesive patch. The company is focused on development of its lead product candidate, M207, a formulation of zolmitriptan, which is used as an acute treatment for migraine. Its zolmitriptan formulation is delivered utilizing its system. M207 is designed to provide rapid absorption of zolmitriptan into the bloodstream without dependence on the gastrointestinal (GI) tract.
Can you provide the latest stock price for Zosano Pharma Corporation?
The current stock price of ZSAN is 0.5576 null. The price increased by 7.23% in the last trading session.
Does Zosano Pharma Corporation pay dividends?
ZSAN does not pay a dividend.
What is the ChartMill technical and fundamental rating of ZSAN stock?
ZSAN has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Is Zosano Pharma Corporation (ZSAN) expected to grow?
The Revenue of Zosano Pharma Corporation (ZSAN) is expected to decline by -90.9% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is the next earnings date for ZSAN stock?
Zosano Pharma Corporation (ZSAN) will report earnings on 2022-08-08.
ZSAN Technical Analysis
ZSAN Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ZSAN. ZSAN has a bad profitability rating. Also its financial health evaluation is rather negative.
ZSAN Financial Highlights
Over the last trailing twelve months ZSAN reported a non-GAAP Earnings per Share(EPS) of -8.41. The EPS decreased by -1951.22% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -8362.12% | ||
| ROA | -208.66% | ||
| ROE | 41.36% | ||
| Debt/Equity | 0 |
ZSAN Forecast & Estimates
7 analysts have analysed ZSAN and the average price target is 21.42 null. This implies a price increase of 3741.46% is expected in the next year compared to the current price of 0.5576.
For the next year, analysts expect an EPS growth of 98.64% and a revenue growth -90.9% for ZSAN